A more recent comprehensive study using SHP2 and KRAS-G12C inhibitor combinations in vitro and in vivo in both xenograft and syngeneic PDAC and NSCLC models showed a benefit of the combination. This evidence concerns the gene KRAS and non-small cell lung carcinoma.